Developer docs
API playgroundTry for free, no card

Search company profiles

Spinogenix

Full company profile

uuid0000gog

Namestring
Spinogenix
Legal namestring
Spinogenix, Inc.
Websiteurl
spinogenix.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Spinogenix, Inc. is a clinical-stage biopharmaceutical company founded in 2016 by Stella Sarraf, PhD and headquartered in Los Angeles, California (incorporated in Delaware). The company develops first-in-class once-daily oral small molecules designed to regenerate and correct synapses in the central nervous system, targeting neurodegenerative, neuropsychiatric, and neurodevelopmental conditions characterized by synaptic loss and dysfunction. Its portfolio consists of two core assets: tazbentetol (formerly SPG302), built on the proprietary TAGS™ (Transient Activators of Glutamatergic Synapses) platform, which triggers neurons to produce new glutamatergic synapses and is being studied in amyotrophic lateral sclerosis (ALS), Alzheimer's disease, schizophrenia, and glaucoma; and SPG601, a first-in-class oral modulator of large-conductance calcium-activated potassium (BK) channels being developed for Fragile X Syndrome.

Spinogenix has received FDA Orphan Drug Designation for both candidates (in ALS and FXS), FDA Fast Track Designation for both, and EMA Orphan Drug Designation for both. Tazbentetol demonstrated rapid, sustained cognitive improvement in a Phase 2a Alzheimer's study (nearly 3-point MMSE increase within four weeks, sustained through 24 weeks) and an 82% rate of stable or improved disease trajectory in a Phase 2a ALS study (76% slower progression versus PRO-ACT historical controls through six months). SPG601 completed a Phase 2a in FXS showing reduced abnormal gamma band activity and improved attention/inhibitory control, and a CLARITY Phase 2b/3 trial has been initiated. An FDA-authorized Expanded Access Program provides tazbentetol to up to 200 ALS patients in the United States ineligible for clinical trials.

The company is pre-revenue. Its business model is conventional clinical-stage biopharma economics: generate value through advancement of investigational assets to regulatory approval and subsequent commercialization or out-licensing, with capital sourced from a mix of NIH and Department of Defense grants and exempt securities offerings (a $25 million offering filed in 2024 with $2.8 million sold, followed by a $35 million offering in 2025 with $10.6 million sold to five investors as of November 2025). Distribution is exclusively through clinical trial sites in Australia and the United States and through the Expanded Access Program, with no commercial sales channel. Leadership includes former Merck executives, the former CEO of Clarivate and IHS Markit (Jerre Stead) as Board Chair, and a Scientific Advisory Board anchored by the world's leading glaucoma expert.

Short descriptiontext

Spinogenix is a clinical-stage biopharmaceutical company developing first-in-class once-daily oral small molecules designed to regenerate and correct synapses, targeting ALS, Alzheimer's disease, schizophrenia, Fragile X Syndrome, and glaucoma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
synaptic regenerative therapeutics, neurodegenerative disease treatment, small molecule pharmaceuticals, clinical-stage biopharmaceuticals, rare disease therapeutics
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-stage neuropharmaceuticals (synaptic regenerative therapeutics)
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development
TypeOne Time License
Description

Spinogenix is a clinical-stage biopharmaceutical company with no current revenue. The company is developing two novel therapeutics: tazbentetol (SPG302) for ALS, Alzheimer's disease, and schizophrenia, and SPG601 for Fragile X Syndrome. Revenue generation is contingent on successful clinical development and regulatory approval.

spinogenix.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Operations, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Spinogenix is developing two investigational, first-in-class oral small molecule therapeutics that restore or correct brain synapses. Tazbentetol (formerly SPG302), built on the proprietary TAGS™ platform, regenerates glutamatergic synapses and is being evaluated in Phase 2 trials for ALS, Alzheimer's disease, and schizophrenia. SPG601 is a BK channel modulator in Phase 2 development for Fragile X Syndrome. Both candidates are administered as once-daily oral pills and are distributed exclusively through clinical trials and an FDA-authorized Expanded Access Program.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 82% of ALS patients treated with tazbentetol showed stable or improved rate of decline at end of treatment
+3 more records
Product overview1 text field

Spinogenix is a clinical-stage biopharmaceutical company pioneering first-in-class synaptic regenerative and synaptic corrective therapeutics designed to restore depleted synapses and reverse synaptic degeneration and dysfunction. The company's portfolio consists of two novel investigational therapeutics: tazbentetol (SPG302), built on the proprietary TAGS™ (Transient Activators of Glutamatergic Synapses) platform, which triggers neurons to produce new glutamatergic synapses to restore cognitive, motor, and other functions across multiple indications including ALS, Alzheimer's disease, schizophrenia, and glaucoma; and SPG601, a BK channel modulator that corrects specific synaptic dysfunctions in Fragile X Syndrome. Both therapeutics are administered as once-daily oral tablets.

Product and service2 records
1Tazbentetol (formerly SPG302)
CategoryInvestigational small molecule therapeutic (synaptic regenerative)
Description

First-in-class, once-daily oral small molecule therapeutic built on the proprietary TAGS™ (Transient Activators of Glutamatergic Synapses) platform. Designed to trigger neurons to produce new glutamatergic synapses and restore cognitive, motor, and other functions in patients with ALS, Alzheimer's disease, schizophrenia, and related neurodegenerative/neuropsychiatric conditions. Currently distributed exclusively through clinical trials and an FDA-authorized Expanded Access Program for ALS.

2SPG601
CategoryInvestigational small molecule therapeutic (BK channel modulator)
Description

First-in-class, once-daily oral small molecule designed to modulate large-conductance calcium-activated potassium (BK) channels to correct specific synaptic dysfunctions underlying core symptoms of Fragile X Syndrome, including cognitive, emotional, and sensory impairments. Currently administered through clinical trials.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-15
Description

Dr. Craig Erickson, Spinogenix Chief Medical Advisor, serves as principal investigator at Cincinnati Children's Hospital within the IMPACT network, a 10-site international research consortium. The hospital received a $17.25 million, five-year grant from ARIA initiative to study EEG biomarkers and genomic analysis for precision medicine approaches to autism, with Dr. Erickson's work including Spinogenix's SPG601 compound research.

2University of California San Diego (Shiley Eye Institute)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-10-16
Description

Dr. Robert N. Weinreb joined Spinogenix's Scientific Advisory Board as Chair and Distinguished Professor of Ophthalmology at UC San Diego and Director of the Shiley Eye Institute. Dr. Weinreb is recognized as the #1 expert in world glaucoma and supports the company's glaucoma program development.

spinogenix.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Dr. Justin K. Ichida, Associate Professor at Keck School of Medicine at USC, serves on Spinogenix's Scientific Advisory Board. His research focuses on neurodegenerative diseases including ALS and frontotemporal dementia, bringing expertise in stem cell biology and regenerative medicine.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Clinical-stage biotech developing small molecule and biologic therapeutics for neurodegeneration including ALS, Alzheimer's, and Parkinson's. Most directly comparable peer given overlapping neurological indications and clinical stage.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing oral small molecules for Alzheimer's disease, Rett syndrome, and other neurodegenerative diseases. Direct peer given similar CNS indications and small molecule approach.

TypeDirect peer
Description

CNS-focused biopharmaceutical company with FDA-approved Zurzuvae for postpartum depression and pipeline targeting neurological/psychiatric disorders. Direct peer given CNS focus and small molecule development.

TypeDirect peer
Description

Clinical-stage biotech developing therapies for neurodegenerative diseases including Parkinson's, Alzheimer's, and ALS. Comparable in therapeutic area focus and clinical stage.

TypeBroad incumbent
Description

Established CNS-focused biopharma with FDA-approved products including Nuplazid for Parkinson's psychosis and Daybue for Rett syndrome. Broader incumbent with commercial CNS portfolio, overlapping with Spinogenix's targeted indications.

TypeDirect peer
Description

Clinical-stage biopharma developing precision medicines for brain diseases including schizophrenia and neurodegenerative disorders. Comparable clinical stage and CNS therapeutic focus.

TypeBroad incumbent
Description

CNS-focused biopharma with FDA-approved Auvelity for major depressive disorder and pipeline in Alzheimer's agitation and other neurological conditions. Broader CNS incumbent with overlapping neurological indications.

TypeEmerging player
Description

Clinical-stage biopharma using AI to develop CNS therapies with focus on agitation in dementia and other neurological conditions. Comparable as clinical-stage CNS drug developer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spinogenix

Clinical-stage neuropharmaceuticals (synaptic regenerative therapeutics)spinogenix.com

Spinogenix is a clinical-stage biopharmaceutical company developing first-in-class once-daily oral small molecules designed to regenerate and correct synapses, targeting ALS, Alzheimer's disease, schizophrenia, Fragile X Syndrome, and glaucoma.

What Spinogenix does

Spinogenix, Inc. is a clinical-stage biopharmaceutical company founded in 2016 by Stella Sarraf, PhD and headquartered in Los Angeles, California (incorporated in Delaware). The company develops first-in-class once-daily oral small molecules designed to regenerate and correct synapses in the central nervous system, targeting neurodegenerative, neuropsychiatric, and neurodevelopmental conditions characterized by synaptic loss and dysfunction. Its portfolio consists of two core assets: tazbentetol (formerly SPG302), built on the proprietary TAGS™ (Transient Activators of Glutamatergic Synapses) platform, which triggers neurons to produce new glutamatergic synapses and is being studied in amyotrophic lateral sclerosis (ALS), Alzheimer's disease, schizophrenia, and glaucoma; and SPG601, a first-in-class oral modulator of large-conductance calcium-activated potassium (BK) channels being developed for Fragile X Syndrome.

Spinogenix has received FDA Orphan Drug Designation for both candidates (in ALS and FXS), FDA Fast Track Designation for both, and EMA Orphan Drug Designation for both. Tazbentetol demonstrated rapid, sustained cognitive improvement in a Phase 2a Alzheimer's study (nearly 3-point MMSE increase within four weeks, sustained through 24 weeks) and an 82% rate of stable or improved disease trajectory in a Phase 2a ALS study (76% slower progression versus PRO-ACT historical controls through six months). SPG601 completed a Phase 2a in FXS showing reduced abnormal gamma band activity and improved attention/inhibitory control, and a CLARITY Phase 2b/3 trial has been initiated. An FDA-authorized Expanded Access Program provides tazbentetol to up to 200 ALS patients in the United States ineligible for clinical trials.

The company is pre-revenue. Its business model is conventional clinical-stage biopharma economics: generate value through advancement of investigational assets to regulatory approval and subsequent commercialization or out-licensing, with capital sourced from a mix of NIH and Department of Defense grants and exempt securities offerings (a $25 million offering filed in 2024 with $2.8 million sold, followed by a $35 million offering in 2025 with $10.6 million sold to five investors as of November 2025). Distribution is exclusively through clinical trial sites in Australia and the United States and through the Expanded Access Program, with no commercial sales channel. Leadership includes former Merck executives, the former CEO of Clarivate and IHS Markit (Jerre Stead) as Board Chair, and a Scientific Advisory Board anchored by the world's leading glaucoma expert.

Spinogenix firmographics

Firmographics
Name
Spinogenix
Legal name
Spinogenix, Inc.
Website
https://spinogenix.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Spinogenix is a clinical-stage biopharmaceutical company developing first-in-class once-daily oral small molecules designed to regenerate and correct synapses, targeting ALS, Alzheimer's disease, schizophrenia, Fragile X Syndrome, and glaucoma.
Ownership category
akta.pro rank

Where Spinogenix is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Spinogenix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales

Revenue model

  1. Pharmaceutical Drug Development: Spinogenix is a clinical-stage biopharmaceutical company with no current revenue. The company is developing two novel therapeutics: tazbentetol (SPG302) for ALS, Alzheimer's disease, and schizophrenia, and SPG601 for Fragile X Syndrome. Revenue generation is contingent on successful clinical development and regulatory approval.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels9 records

Spinogenix product offering

Product offering

Core offering

Spinogenix is developing two investigational, first-in-class oral small molecule therapeutics that restore or correct brain synapses. Tazbentetol (formerly SPG302), built on the proprietary TAGS™ platform, regenerates glutamatergic synapses and is being evaluated in Phase 2 trials for ALS, Alzheimer's disease, and schizophrenia. SPG601 is a BK channel modulator in Phase 2 development for Fragile X Syndrome. Both candidates are administered as once-daily oral pills and are distributed exclusively through clinical trials and an FDA-authorized Expanded Access Program.

Product overview

Spinogenix is a clinical-stage biopharmaceutical company pioneering first-in-class synaptic regenerative and synaptic corrective therapeutics designed to restore depleted synapses and reverse synaptic degeneration and dysfunction. The company's portfolio consists of two novel investigational therapeutics: tazbentetol (SPG302), built on the proprietary TAGS™ (Transient Activators of Glutamatergic Synapses) platform, which triggers neurons to produce new glutamatergic synapses to restore cognitive, motor, and other functions across multiple indications including ALS, Alzheimer's disease, schizophrenia, and glaucoma; and SPG601, a BK channel modulator that corrects specific synaptic dysfunctions in Fragile X Syndrome. Both therapeutics are administered as once-daily oral tablets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Tazbentetol (formerly SPG302) First-in-class, once-daily oral small molecule therapeutic built on the proprietary TAGS™ (Transient Activators of Glutamatergic Synapses) platform. Designed to trigger neurons to produce new glutamatergic synapses and restore cognitive, motor, and other functions in patients with ALS, Alzheimer's disease, schizophrenia, and related neurodegenerative/neuropsychiatric conditions. Currently distributed exclusively through clinical trials and an FDA-authorized Expanded Access Program for ALS.
  • SPG601 First-in-class, once-daily oral small molecule designed to modulate large-conductance calcium-activated potassium (BK) channels to correct specific synaptic dysfunctions underlying core symptoms of Fragile X Syndrome, including cognitive, emotional, and sensory impairments. Currently administered through clinical trials.

Quantifiable outcome

  • 82% of ALS patients treated with tazbentetol showed stable or improved rate of decline at end of treatment
  • +3 more outcomes

Companies that use Spinogenix

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Spinogenix technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Spinogenix partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Cincinnati Children's HospitalcoreStrategic or Co-development Partner · 15 June 2026Dr. Craig Erickson, Spinogenix Chief Medical Advisor, serves as principal investigator at Cincinnati Children's Hospital within the IMPACT network, a 10-site international research consortium. The hospital received a $17.25 million, five-year grant from ARIA initiative to study EEG biomarkers and genomic analysis for precision medicine approaches to autism, with Dr. Erickson's work including Spinogenix's SPG601 compound research.
  • University of California San Diego (Shiley Eye Institute)minorStrategic or Co-development Partner · 16 October 2024Dr. Robert N. Weinreb joined Spinogenix's Scientific Advisory Board as Chair and Distinguished Professor of Ophthalmology at UC San Diego and Director of the Shiley Eye Institute. Dr. Weinreb is recognized as the #1 expert in world glaucoma and supports the company's glaucoma program development.
  • University of Southern CaliforniaminorStrategic or Co-development Partner · 1 January 2024Dr. Justin K. Ichida, Associate Professor at Keck School of Medicine at USC, serves on Spinogenix's Scientific Advisory Board. His research focuses on neurodegenerative diseases including ALS and frontotemporal dementia, bringing expertise in stem cell biology and regenerative medicine.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Spinogenix competitors and assessment

Company assessment

Direct peers

  • Denali Therapeutics: Clinical-stage biotech developing small molecule and biologic therapeutics for neurodegeneration including ALS, Alzheimer's, and Parkinson's. Most directly comparable peer given overlapping neurological indications and clinical stage.
  • Anavex Life Sciences: Clinical-stage biopharmaceutical company developing oral small molecules for Alzheimer's disease, Rett syndrome, and other neurodegenerative diseases. Direct peer given similar CNS indications and small molecule approach.
  • Sage Therapeutics: CNS-focused biopharmaceutical company with FDA-approved Zurzuvae for postpartum depression and pipeline targeting neurological/psychiatric disorders. Direct peer given CNS focus and small molecule development.
  • Prothena Corporation: Clinical-stage biotech developing therapies for neurodegenerative diseases including Parkinson's, Alzheimer's, and ALS. Comparable in therapeutic area focus and clinical stage.
  • Neumora Therapeutics: Clinical-stage biopharma developing precision medicines for brain diseases including schizophrenia and neurodegenerative disorders. Comparable clinical stage and CNS therapeutic focus.

Broad incumbents

  • Acadia Pharmaceuticals: Established CNS-focused biopharma with FDA-approved products including Nuplazid for Parkinson's psychosis and Daybue for Rett syndrome. Broader incumbent with commercial CNS portfolio, overlapping with Spinogenix's targeted indications.
  • Axsome Therapeutics: CNS-focused biopharma with FDA-approved Auvelity for major depressive disorder and pipeline in Alzheimer's agitation and other neurological conditions. Broader CNS incumbent with overlapping neurological indications.

Emerging players

  • BioXcel Therapeutics: Clinical-stage biopharma using AI to develop CNS therapies with focus on agitation in dementia and other neurological conditions. Comparable as clinical-stage CNS drug developer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Spinogenix social profiles

Digital presence

Spinogenix compliance and trust

Trust signal

Compliance6 records

Spinogenix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spinogenix leadership team

Management profile

Number of profiles

Profiles7 records

Spinogenix funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spinogenix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spinogenix

What does Spinogenix do?

Spinogenix is developing two investigational, first-in-class oral small molecule therapeutics that restore or correct brain synapses. Tazbentetol (formerly SPG302), built on the proprietary TAGS™ platform, regenerates glutamatergic synapses and is being evaluated in Phase 2 trials for ALS, Alzheimer's disease, and schizophrenia. SPG601 is a BK channel modulator in Phase 2 development for Fragile X Syndrome. Both candidates are administered as once-daily oral pills and are distributed exclusively through clinical trials and an FDA-authorized Expanded Access Program.

Is Spinogenix a public or private company?

Spinogenix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Spinogenix founded?

Spinogenix was founded in 2016. It employs 1 to 10 people.

Where is Spinogenix based?

Spinogenix is headquartered in Los Angeles, United States, in the North America region.

How does Spinogenix make money?

One revenue line is on record: pharmaceutical Drug Development.

Who are Spinogenix's main competitors?

Direct peers on record are Denali Therapeutics, Anavex Life Sciences, Sage Therapeutics, Prothena Corporation and Neumora Therapeutics. Broad incumbents are Acadia Pharmaceuticals and Axsome Therapeutics. BioXcel Therapeutics is listed as an emerging player.

Does Spinogenix have an API?

No public API is recorded for Spinogenix.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Neurology liveFDA Clears Phase 1/2 Clinical Trial for Spinogenix’s ALS Treatment SPG302The FDA has cleared the investigational new drug application for Spinogenix's SPG302, allowing the company to proceed with a Phase 1/2 clinical trial for its ALS treatment. This approval follows successful initial dosing in healthy volunteers in Australia and grants Spinogenix access to orphan drug benefits such as fee exemptions. The upcoming trial will evaluate the safety and efficacy of the once-daily pill, which aims to regenerate synapses to reverse cognitive and motor decline associated with ALS.Psychiatric TimesFirst Synaptic Regenerative Therapy for Schizophrenia Under InvestigationSpinogenix has initiated a phase 2 clinical trial for SPG302, the first synaptic regenerative therapy for schizophrenia, following approval by the Australia Human Research Ethics Committee. The study aims to evaluate the efficacy and safety of this oral tablet in addressing glutamatergic synapse loss, a key feature of the disease's pathogenesis. This development represents a novel therapeutic approach distinct from traditional dopamine-targeting antipsychotics.Neurology liveFDA Authorizes Expanded Access Program for ALS Treatment SPG302The FDA has authorized an expanded access program for SPG302, an investigational small molecule therapy developed by Spinogenix, to treat amyotrophic lateral sclerosis (ALS) in the United States. This authorization follows the completion of a phase 1/2 trial in Australia and aims to collect real-world data on the drug's safety and efficacy while addressing synapse loss associated with the disease. The company anticipates significant clinical milestones for SPG302 in 2025 as it continues development under orphan drug designation.Neurology liveFindings From First Cohort of SPG302 in Phase 2 Alzheimer Disease Trial: Sharron Gargosky, PhDSpinogenix presented initial findings from the first cohort of its Phase 2 trial for SPG302, a novel synaptogenic small molecule designed to treat mild-to-moderate Alzheimer's disease. The study results indicated that the treatment was safe and well-tolerated over 28 weeks, with participants showing early signs of cognitive improvement. These positive signals support the continued development of SPG302 as both a standalone therapy and an adjunct to existing standard of care.Applied Clinical TrialsSpinogenix Receives Positive FDA Feedback for SPG601 in Fragile X SyndromeSpinogenix received positive feedback from the FDA regarding its SPG601 therapy for Fragile X syndrome following a Type C meeting. The company's Phase IIa trial successfully met its primary endpoint, demonstrating improvements in neurophysiological activity and cognitive function compared to placebo. This regulatory guidance supports Spinogenix in designing future registrational trials to advance the drug toward potential approval.Neurology liveFDA AdComm Votes Against Recommending Deramiocel Approval, Tazbentetol Shows Durable Cognitive Benefit in AD, Salanersen's FDA Breakthrough Designation MeaningThe FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 against recommending approval for Capricor Therapeutics' deramiocel for treating cardiomyopathy in Duchenne muscular dystrophy patients, citing concerns about statistical stability of efficacy endpoints and whether LVEF serves as a validated surrogate marker, ahead of the August 2026 PDUFA date. At the 2026 Alzheimer's Association International Conference in London, Spinogenix presented data showing its investigational therapy tazbentetol produced durable cognitive improvement in mild-to-moderate Alzheimer's disease patients for up to 84 weeks in a compassionate use program, with no treatment-related adverse events. Additionally, the FDA granted Breakthrough Therapy Designation to Biogen's salanersen for spinal muscular atrophy based on Phase 1b data showing motor function improvements in children who had suboptimal responses to prior gene therapy.AijournSpinogenix Announces World Health Organization Approval of “Codabakalner” as International Nonproprietary Name for SPG601Spinogenix announced that the WHO's International Nonproprietary Names Expert Committee approved "codabakalner" as the non-proprietary name for their investigational therapy SPG601, a first-in-class oral treatment for Fragile X syndrome. The therapy is a positive modulator of BK channels designed to correct synaptic dysfunction underlying cognitive, behavioral, and sensory symptoms, and has received Orphan Drug and Fast Track designation from the FDA as well as orphan medicinal product designation from the EMA. The company is preparing to initiate the CLARITY Phase 2b/3 registrational trial for the treatment.PR NewswireSpinogenix Announces World Health Organization Approval of "Codabakalner" as International Nonproprietary Name for SPG601Spinogenix announced the World Health Organization approved "codabakalner" as the nonproprietary name for its investigational therapy SPG601 for Fragile X syndrome. The oral therapy is a first-in-class positive modulator of BK channels, and the company plans a Phase 2b/3 trial called CLARITY.AInvestSpinogenix: The Synaptic Regeneration Bet Wall Street Doesn't Understand YetSpinogenix reported Phase 2a data for its Alzheimer's drug tazbentetol in December 2025, showing a non-statistically significant half-point improvement on the CDR-SB primary endpoint but early improvements on the SMMSE cognitive measure. The drug uses a first-in-class synaptic regeneration mechanism targeting structural neuronal damage rather than protein clearance, differentiating it from existing Alzheimer's therapies. The FDA granted Fast Track designation for tazbentetol in ALS in May 2026, while Phase 2 schizophrenia trial data presented in March 2026 showed PANSS score reductions versus placebo, giving the company three indications advancing in parallel.AijournSpinogenix Reports Positive Data on Alzheimer’s Patients Who Continued Treatment With Tazbentetol For Up To 84 WeeksSpinogenix announced extended data showing its investigational drug Tazbentetol (SPG302) demonstrated favorable safety and durable cognitive benefits for up to 84 weeks in Alzheimer's disease patients who continued treatment under a compassionate use Special Access Scheme. The Phase 2a trial, conducted in Australia with 24 mild-to-moderate AD patients, showed sustained improvement on cognitive measures including SMMSE and CDR-SB through approximately 19 months of treatment. A case study presented at AAIC 2026 highlighted a 72-year-old patient who showed rapid cognitive improvement within three months of treatment with observable functional gains.